

# West Virginia Medicaid Drug Utilization Review Board Minutes

November 20, 2019

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance;

## **Members:**

Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
C.K. Babcock, PharmD  
Chris Booth, PharmD  
Scott Brown, RPh  
Myra Chiang, MD  
Phillip Galapon, MD  
David Gloss, MD  
Michael Lonsinger, PharmD  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS  
Christopher Terpening, PharmD, PhD  
John Vanin, MD

## **Members Absent:**

Michael Ballow, PharmD  
Kate Forman, PharmD

## **DHHR/BMS Staff:**

Brian Thompson, MS, PharmD, Director of Pharmacy Services  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy operations Manager  
Doug Sorvig, Administrative Assistant

## **Contract Staff:**

Chris Hale, PharmD, Rational Drug Therapy Program (RDTP)  
Alesha Heil, PharmD, SEMP  
Rob Stanton, PharmD, Marshall University  
Kim Broedel-Zaugg, RPh, PhD, Marshall University  
Sarah Plummer, PharmD, Marshall University  
Eric Sears, RPh, DXC  
Brent Breeding, RPh, Change Healthcare

### **I. INTRODUCTIONS**

- a. Dr. Lester Labus, Chair, welcomed everyone to the Board meeting at 4:02pm EDT. The DUR Board and attendees introduced themselves.

### **II. APPROVAL OF MINUTES FROM September 25, 2019 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

### III. OLD BUSINESS

- a. The nominations committee met and presented the following slate:
  - Chair: KC Lovin
  - Vice Chair: Chris TerpeningNo nominations were received from the floor. A motion was made to accept the slate.  
Motion approved.

### IV. NEW BUSINESS

- a. **Speakers**
  - i. none
- b. **Updates from August 28, 2019 P & T Committee Meeting**
  - i. Mr. Breeding presented the updates from the October 30, 2019 P & T meeting for board review. No changes were requested.
- c. **PDL Prior Authorization Criteria.** Attachment A
  - i. **Hemlibra:** approved as presented.
  - ii. **Sunosi:** approved as presented.
  - iii. **Cytokine agents – Acitretin for plaque psoriasis:** approved as presented.
  - iv. **CGRP Antagonists:** approved as presented.
  - v. **Testosterone Replacement Therapy:** approved as presented.
  - vi. **Atypical Antipsychotics- Latuda:** approved as presented.
  - vii. **Orlissa:** approved as amended. NSAID use may be documented. Patient has failed a 90-day trial of each of the following: a) GnRH agonist and b) an extended-cycle combined oral contraceptive OR progestin therapy.
  - viii. **MS Agents:** approved as presented.
  - ix. **PCSK9 inhibitors:** approved as presented.
  - x. **Zetia:** approved as presented.
  - xi. **Linzess:** approved as presented.
  - xii. **Motegrity:** approved as presented
  - xiii. **Ophthalmics, anti-inflammatories-immunomodulators:** approved as amended. Multiple dose containers must be approved on appeal
  - xiv. **Rho-kinase inhibitors:** approved as presented.
  - xv. **Fasenra:** approved as presented.
  - xvi. **Trikafta:** approved as presented.

### V. REPORTS

- a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2019 Third Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Hale presented a review of the prior authorization program for the Third Quarter of 2019. Attachment C
- c. **Marshall University Coalition:** Dr. Stanton reported on the progress of retro DUR, the lock in program, and number of letters sent/returned. Attachment D

### VI. OTHER BUSINESS

- a. none

**VII. NEXT MEETING AND ADJOURNMENT**

- VIII.**
- a. A motion to adjourn the meeting was made, seconded, and approved.
  - b. The meeting concluded at 5:32pm EDT.
  - c. The next meeting will be February 19, 2020 from 4:00pm to 6:00pm and located at WVDHHR.